FDA Approves First Disease-Modifying Drug for Rare Neurological Disorder Alexander Disease

Families managing Alexander disease now have a treatment that actively slows the condition's progression, replacing a standard of care that could only offer symptom relief. The U.S. Food and Drug Administration approved zilganersen, marketed as Zanvastro, on September 3, 2026, marking the first disease-modifying therapy for the ultra-rare neurological disorder.[1][2]

Alexander disease affects fewer than one in a million people worldwide. It is driven by a genetic mutation that causes the overproduction of glial fibrillary acidic protein (GFAP). This abnormal protein accumulates in the brain's supportive cells, damaging neurons and myelin, which leads to a progressive loss of muscle control, seizures, and difficulty speaking or swallowing.[1][4]

Zilganersen, developed by Ionis Pharmaceuticals, is an antisense oligonucleotide designed to intercept this process. Rather than managing the resulting seizures or muscle weakness, the drug reduces the production of the toxic GFAP protein before it can accumulate and cause further neurological damage.[1][5]

The regulatory clearance rests on a Phase 3 clinical trial involving 54 patients aged 1.5 to 53 years. Because the disease is exceptionally rare, the FDA evaluated data across a wide age range to support an indication covering patients from infancy through adulthood.[1][2]

In the trial, patients aged five and older who received the drug maintained their walking speed over 61 weeks, as measured by a 10-meter walk test. By contrast, patients in the untreated control group experienced a decline in walking speed of approximately 35 percent over the same period.[2][5]

For younger children aged two to four, researchers used a gross motor function composite that evaluated standing, walking, running, and jumping. Children treated with zilganersen showed improvements on these measures, whereas those in the control group continued to decline.[2][5]

Administration of the new therapy introduces specific logistical requirements for patients and healthcare providers. The drug is delivered as a 50-milligram intrathecal injection directly into the spinal canal every three months.[4][5]

This quarterly dosing schedule means preparation and administration will be managed in specialty pharmacy and health-system settings. Pharmacists and clinical teams will need to coordinate the specialized handling and procedure logistics required for spinal injections.[4]

The safety profile requires ongoing monitoring by clinical teams. The most common side effects reported during the trial included vomiting, back pain, headache, and post-lumbar puncture syndrome. The FDA also noted that aseptic meningitis occurred in some treated patients, requiring caregivers to watch for symptoms of the condition following administration.[1][2]

Emily Freilich, M.D., director of the Division of Neurology I in the FDA's Center for Drug Evaluation and Research, characterized the decision as a structural shift for patients. "Today's approval is a landmark moment for this community, offering the first therapy that addresses the underlying cause of this rare and serious disease," she stated.[1]

The introduction of a targeted therapy changes the immediate steps for diagnosed patients. Medical teams will now focus on transitioning eligible individuals to the quarterly injection schedule and establishing baseline metrics to monitor long-term motor function stabilization.[6]